Back to results
US 2026/0216130 A1Published application
Envenomation therapies and related pharmaceutical compositions, systems and kits
AssigneeOphirex, Inc.
InventorMatthew R. Lewin
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOphirex, Inc.
InventorMatthew R. Lewin
Estimating the term…
The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and/or adjunct therapy with antivenom using at least one active component, in some instances at least two active components and in other instances no more than two active components selected from the group consisting of a selective secretory PLA2 inhibitor (sPLA2 or PLA2 inhibitor), a metalloproteinase inhibitor, a serine protease inhibitor, antivenom, one or more acetylcholinesterase inhibitors or a nAChR agonist paired with a mAChR antagonist, a NMDA receptor antagonist and a spreading factor inhibitor to treat a subject who suffers from an envenomation, preferably at the time of envenomation and often within a period of less than about an hour after an envenomation or 6 hours after an envenomation and throughout the course of treatment at time with or without antivenom as an adjunct therapy after an envenomation by, for example, a snake or invertebrate.
1-123. (canceled)
(Method) A method of treating a patient or subject suffering from envenomation by a snake comprising administering to said patient or subject an effective amount of a PLA2 inhibitor selected from the group consisting of varespladib, methylvarespladib, a pharmaceutically acceptable salt thereof or a mixture thereof in combination with a pharmaceutically acceptable carrier, additive or excipient and at least one additional agent selected from the group consisting of a metalloproteinase inhibitor, a snake antivenom or a mixture thereof, wherein said PLA2 inhibitor is administered to said patient or subject in a separate medicament from said additional agent(s).
The method according to claim 125 wherein said PLA2 inhibitor is administered in combination with a therapeutically effective amount of a snake antivenom.
A method of treating a patient or subject suffering from envenomation by a snake comprising administering to said subject an effective amount of a PLA2 inhibitor selected from the group consisting of varespladib, methylvarespladib, a pharmaceutically acceptable salt thereof or a mixture thereof in combination with neostigmine and a muscarinic acetylcholine receptor (mAChR) inhibitor as additional active agents, wherein said PLA2 inhibitor is administered to said patient or subject in a separate medicament from said additional active agent(s).
Dependencies are inferred from the claim text.